A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

Shares in Novo rose almost 4% after the company revised its outlook and off the back of the sales from Ozempic, which were above forecasts. The company expects 2019 sales growth of 2-5% and ...

Two months ago, when the FDA removed Novo’s drugs from the shortage list and gave compounders a grace period of between 60 and 90 days to halt production of semaglutide, the OFA and FarmaKeio ...

In May 2023, when Novo reported that patients on the highest dose (50 mg) of oral semaglutide lost 15% of their weight after 64 weeks, the company said it planned to apply for approval by the end ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

Novo Nordisk, a leading global healthcare company, announced that the US Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg ...

Patients are encouraged to only acquire authentic Novo Nordisk Ozempic ® (semaglutide) injection 1 mg through pharmacies and to check the product for any signs of counterfeiting before using.

"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of semaglutide is resolved, said Steve Benz, Novo Nordisk's corporate ...